BTK and acute myeloid leukemia: For instance, QL-X-138 targets both BTK/MNK kinase and effectively induces apoptosis in lymphoma and leukemia cells57, and TAK-659 is a dual SYK/FLT-3 inhibitor that has displayed notable antitumor growth activity in clinical trials for FLT3-dependent AML and advanced solid tumor and lymphoma malignancies58.